Navigation Links
Avexa Reports Positive Phase IIb Result

und 1.4 million people in North America and around 2.2 million people in Europe have HIV.

Once on therapy, patients with HIV will typically take a minimum of 3 drugs daily in combination. This may increase as a patient progresses into 2nd and 3rd line therapy or into salvage therapy, when patients develop what is commonly referred to as AIDS. Second line patients are defined as patients who show resistance to at least one class of HIV drugs, while 3rd line and salvage patients typically have resistance to multiple drugs and drug classes. Avexa aims to position ATC as the NRTI of choice for treatment of patients in 2nd and 3rd line therapy and salvage therapy, as well as the growing number of treatment naive patients presenting with HIV virus resistant to current front line therapies. In 2005 HIV drugs generated sales globally of USD $6.6 billion, with NRTIs representing greater than 50% of the overall market.

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials.

Technical Data

Trial Design

AVX-201 is a randomised, double blind study of two doses of ATC compared to lamivudine (3TC) in treatment-experienced HIV-1 infected patients with the M184V mutation. Patients were randomised to receive 600mg or 800mg ATC twice daily, or 3TC twice daily, for 21 days, in a blinded fashion. The primary endpoint of the study is the change in the amount of virus in the blood (viral load) after 21 days treatment.

After day 2
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avexas Apricitabine Clinical Trial Update
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Reports Positive Phase IIb Result
(Date:3/5/2015)... and HAMPTON, N.J. , March 5, ... MNK ), a leading global specialty biopharmaceutical company, ... today that they have entered into a definitive agreement ... Inc. from a Madison Dearborn -led investor group ... Subject to customary closing conditions, the parties ...
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Global Rising Stars Outlook 2015" report to their ... are being sought after with fresh vigor as new ... which is poised to bring a paradigm change in ... is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... -- According to a new market research ... Disposables), by Type (Invasive, Minimally Invasive, Non-Invasive), by End-User ... - Analysis & Global Forecast to 2019" , the ... $1,107.4 Million by 2019 from $887.8 Million in 2014, ... 4.5% during the forecast period. Browse ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... STEWARTVILLE, Minn., Oct. 25 Rochester Medical Corporation (Nasdaq: ... close on Thursday, November 4, 2010.  The Company will then ...  The call will begin at 3:30 p.m. central time (4:30 ... by Thomson/CCBN and can be accessed at Rochester Medical,s website ...
Cached Medicine Technology:Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 2Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 3Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 4Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 5Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 6Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 7Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 8Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 9Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 10Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 11Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010 2
(Date:3/5/2015)... 2015 Shania Twain will be touring ... decade. She has hinted that this will be her final ... perform one last time. She has had a residency in ... sweetheart has millions of loyal fans around the world. After ... Canada, and on June 30th she will be at Madison Square ...
(Date:3/5/2015)... York, New York (PRWEB) March 05, 2015 ... of men who allegedly suffered heart attacks, strokes and ... prescription low testosterone therapies continue to move forward in ... Court, Northern District of Illinois. According to a Case ... set forth procedures for the use of master pleadings ...
(Date:3/5/2015)... Los Angeles, CA (PRWEB) March 05, 2015 ... online article titled “Butt Augmentation, Labiaplasty on the Rise, ... surveys reported by the American Society for Aesthetic ... Plastic Surgeons . Both groups reported a year-over-year doubling ... one of the physicians quoted in the article, this ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... in healthcare communications and education, announced today its ... (AMP), the nation’s only medical conference designed for ... ischemia and lower limb amputation due to vascular ... family of innovative, evidence-based publications and CME activities ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2
... Glenn Hackbarth (MedPAC) and Bruce Bradley (General,Motors) - ... 1 The ABIM Foundation,will dedicate its efforts ... concepts,of medical professionalism and accountability in health care ... In addition, the Foundation announced that officers of ...
... Care Advantage, JACKSONVILLE, Fla., July 1 ... home,health care agency with 11 years experience in ... in revenue. Home Care Advantage is the largest ... the largest,rehabilitation provider in Jacksonville, with its 143-bed ...
... -- The first batch of imported food,( ... for the Olympic Games has arrived. The 24.269 ... in Shanghai on June 18. To ensure the,smooth ... Quarantine Bureau,took great care in their preparations prior ...
... 20% of persons aged over 55 use colonoscopies for ... insurance funds have covered the costs since 2002. This ... Database published in the current edition of Deutsches ... , http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=60551 , The authors evaluated ...
... What began as a college course project to design ... their kind, designed as therapy for children with cerebral ... affects the development of the brain and the motor ... occupational therapy have been shown to be effective treatments ...
... junk food had higher cholesterol, blood fats into adulthood, ... -- Eating an unhealthy diet during pregnancy may raise ... and blood sugar levels, British researchers report. , In ... one group of females a diet of processed junk ...
Cached Medicine News:Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Jacksonville's Largest Rehab Provider Acquires Largest Home Health Agency 2Health News:China Improves Safety Management on Imported Foods in Preparation for Olympic Games 2Health News:Toys and technology for rehabilitation in cerebral palsy patients 2Health News:Toys and technology for rehabilitation in cerebral palsy patients 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2
... The Bledsoe Revolution Knee ... speed fitting under post-op ... the surgeon or authorized ... post-op fitting and application ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
... Room Knee Brace frees the ... the time-consuming post-op fitting and ... more complex brace designs. The ... provides the same benefits as ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: